JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118
JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.
Share
Why It Matters
A big bank analyst still thinks Abbott is a good pick. But they lowered their price guess by two dollars, which hints at slight caution.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.